Journal article
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Abstract
ObjectivesWe aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, and to identify predictors of response to treatment.MethodsRetrospective review (May 2014–December 2016) of VICTORY Consortium data. Adults with follow-up after starting VDZ for clinically active UC were included. Primary effectiveness outcomes were cumulative rates of clinical remission (resolution of all UC-related symptoms) and endoscopic …
Authors
Narula N; Peerani F; Meserve J; Kochhar G; Chaudrey K; Hartke J; Chilukuri P; Koliani-Pace J; Winters A; Katta L
Journal
The American Journal of Gastroenterology, Vol. 113, No. 9, pp. 1345–1354
Publisher
Wolters Kluwer
Publication Date
September 2018
DOI
10.1038/s41395-018-0162-0
ISSN
0002-9270